Welcome to our dedicated page for Illumina news (Ticker: ILMN), a resource for investors and traders seeking the latest updates and insights on Illumina stock.
Illumina develops DNA sequencing, array-based, informatics and proteomics technologies for research, clinical and applied markets. Company news commonly covers sequencing instruments and consumables, NovaSeq X demand, DRAGEN software releases, TruPath Genome analytical support, and applications in oncology, reproductive health, agriculture, rare disease and drug discovery.
Illumina updates also include collaborations around precision oncology testing, preventive and population genomics, pediatric cancer and rare disease data, and the Alliance for Genomic Discovery. Financial and corporate news covers revenue trends, operating margins, earnings guidance, share repurchase authorizations, acquisitions in multiomics and proteomics, and board or management changes.
Illumina (NASDAQ: ILMN) will release its second quarter 2026 financial results after market close on Thursday, July 30, 2026. Management will host an earnings conference call at 1:30 pm PT (4:30 pm ET), with live webcast and 30-day replay available via the company’s investor website.
Illumina (NASDAQ:ILMN) appointed Mike Sullivan as Chief Commercial Officer effective July 20, 2026, and Julie Coletti as Chief Legal Officer effective August 3, 2026. Both join the Executive Leadership Team as the company advances its strategy in genomics, multiomics, and human health.
Sullivan will lead the global commercial organization, bringing over 30 years of commercial leadership across diagnostics, precision medicine, healthcare, and life sciences. Coletti will oversee global legal, regulatory, and government affairs and serve as corporate secretary, drawing on extensive legal and governance experience in life sciences and medical technology.
Illumina (NASDAQ: ILMN) appointed Daniel M. Skovronsky, MD, PhD, to its Board of Directors, effective June 16, 2026. He is Chief Scientific and Product Officer at Eli Lilly and President of Lilly Research Laboratories.
He brings experience in drug discovery, clinical development, translational medicine, and precision medicine.
IQM Quantum Computers appointed Craig Ciesla, former 10x Genomics (Nasdaq: TXG) VP of Engineering, as Chief Technology Officer and Inés de Vega as Chief Scientist.
The company is preparing for a planned Nasdaq listing via merger with Real Asset Acquisition Corp (Nasdaq: RAAQ), supported by an upsized $146 million PIPE. IQM operates a vertically integrated quantum computing business and has sold 23 quantum computers to date.
Illumina (NASDAQ:ILMN) launched the StrataMap Spatial Solution, an end-to-end, sequencing-based spatial whole-transcriptome platform for single-cell resolution research across large tissue areas.
The system offers up to 2x more unique genes per sample than probe-based panels, supports >2000 samples annually, integrates with NovaSeq/NextSeq, and includes DRAGEN and Illumina Connected Multiomics software for scalable spatial and multiomic analysis. An FFPE-focused version is targeted for initial customer enablement in 2027.
Illumina (NASDAQ: ILMN) and Integrated DNA Technologies announced a collaboration to create end-to-end somatic oncology research workflows. IDT’s xGen FFPE and cfDNA library prep is integrated with Illumina’s DRAGEN secondary analysis, including a new low-quality FFPE mode and compatibility with Illumina Connected Insights for variant interpretation.
Illumina (NASDAQ:ILMN) and SPT Labtech launched fireflyGO, a benchtop automation platform for liquid handling and library preparation in targeted oncology research. Integrated with the MiSeq i100 Series, it automates NGS workflows and supports Pillar Biosciences oncoReveal panels for solid tumor and lymphoid malignancy research.
Illumina is also expanding its oncoReveal portfolio with the Nexus 21 Gene Panel and an 84‑gene Lymphoid Panel, both available worldwide and focused on rapid, simplified genomic characterization of multiple cancer types.
Illumina (NASDAQ:ILMN) unveiled a distributed whole-genome sequencing MRD research solution, enabling labs to study molecular residual disease in solid tumors and blood cancers. The NovaSeq-compatible workflow delivers tumor fingerprinting and blood-based MRD detection in as fast as 5 days, with analytical sensitivity down to 10 ppm and a ctDNA algorithm showing 99.5% analytical specificity. Early access is available now, with global launch planned next year and an ultra-sensitive single-digit ppm duplex-based workflow in development.
Illumina (NASDAQ: ILMN) elected David P. King, former Labcorp Executive Chairman and CEO, to its Board of Directors, effective immediately after the 2026 annual shareholder meeting.
Illumina highlights his regulatory, diagnostics, and healthcare expertise as it advances its clinical genomics strategy. King succeeds retiring directors Frances Arnold, Robert Epstein, and Gary Guthart.
Illumina (NASDAQ: ILMN) released its 2025 Corporate Responsibility Report, emphasizing expanded access to genomics and global impact. Highlights include sequencing over 10 human genomes per minute in 2025, major sustainability gains, workforce equity, large-scale community engagement, and new product launches that broaden research, clinical, and population health applications.